دورية أكاديمية
Hemophagocytic Lymphohistiocytosis Secondary to Tuberculosis After Liver Transplantation: A Case Report.
| العنوان: | Hemophagocytic Lymphohistiocytosis Secondary to Tuberculosis After Liver Transplantation: A Case Report. |
|---|---|
| المؤلفون: | Ferreira GSA; Liver Transplant Division, Federal District Cardiology Institute, Brasilia, Brazil. Electronic address: gustferr@ufmg.br., Moreira ML; General Surgery Division, Doutor Celio de Castro Metropolitan Hospital, Belo Horizonte, Brazil., Watanabe ALC; Liver Transplant Division, Federal District Cardiology Institute, Brasilia, Brazil., Trevizoli NC; Liver Transplant Division, Federal District Cardiology Institute, Brasilia, Brazil., Murta MCB; General Surgery Division, Doutor Celio de Castro Metropolitan Hospital, Belo Horizonte, Brazil., Figueira AVF; Liver Transplant Division, Federal District Cardiology Institute, Brasilia, Brazil., Caja GON; Liver Transplant Division, Federal District Cardiology Institute, Brasilia, Brazil., Ferreira CA; General Surgery Division, Doutor Celio de Castro Metropolitan Hospital, Belo Horizonte, Brazil., Jorge FMF; Liver Transplant Division, Federal District Cardiology Institute, Brasilia, Brazil., Couto CF; Liver Transplant Division, Federal District Cardiology Institute, Brasilia, Brazil. |
| المصدر: | Transplantation proceedings [Transplant Proc] 2022 Jun; Vol. 54 (5), pp. 1384-1387. Date of Electronic Publication: 2022 May 18. |
| نوع المنشور: | Case Reports; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Inc Country of Publication: United States NLM ID: 0243532 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2623 (Electronic) Linking ISSN: 00411345 NLM ISO Abbreviation: Transplant Proc Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York, N.Y. : Elsevier Science Inc. Original Publication: New York Stratton. |
| مواضيع طبية MeSH: | Liver Transplantation*/adverse effects , Lymphohistiocytosis, Hemophagocytic*/diagnosis , Lymphohistiocytosis, Hemophagocytic*/etiology , Mycobacterium tuberculosis* , Tuberculosis*/complications , Tuberculosis*/diagnosis , Tuberculosis*/drug therapy, Antitubercular Agents/therapeutic use ; Child ; Etoposide/therapeutic use ; Humans |
| مستخلص: | Hemophagocytic lymphohistiocytosis (HL) is a rare syndrome characterized by a hyperinflammatory state, resulting from an excessive but ineffective immune response. There is a continuous stimulation of TCD8 + lymphocytes, associated with an uncontrolled release of cytokines, causing the infiltration of multiple organs by histiocytes and activated lymphocytes. HL can be a primary condition as a consequence of genetic disorder that most often affects children, or it can be secondary to neoplasms, autoimmune conditions or various infectious diseases in patients of all ages. HL caused by infection by Mycobacterium tuberculosis is highly unusual, with few cases reported in the literature. There is no clinical manifestation or laboratorial finding that is specific to HL, and a high index of clinical suspicion is necessary for the correct diagnosis, which is usually confirmed by biopsy. Treatment consists of controlling the causative event and the use of immunosuppressant drugs such as corticosteroids, etoposide, and cyclosporine to suppress the exacerbated immune response. We report the case of a patient who developed HL 2 months after liver transplantation. The initial presentation was persistent fever, prompting a search for a site of infection and the use of broad-spectrum antibiotics. As the clinical condition of the patient continued to deteriorate, HL was diagnosed through a bone marrow biopsy, and a cerebrospinal fluid culture positive for M. tuberculosis established the diagnosis of disseminated tuberculosis. Despite optimal treatment with immunosuppressors and antituberculosis drugs, there was no significant response and the patient died. This article is compliant with the Helsinki Congress and the Istanbul Declaration. (Copyright © 2022 Elsevier Inc. All rights reserved.) |
| المشرفين على المادة: | 0 (Antitubercular Agents) 6PLQ3CP4P3 (Etoposide) |
| تواريخ الأحداث: | Date Created: 20220521 Date Completed: 20220823 Latest Revision: 20220823 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.transproceed.2022.03.025 |
| PMID: | 35597674 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1873-2623 |
|---|---|
| DOI: | 10.1016/j.transproceed.2022.03.025 |